Strategies for the treatment of acute myeloid leukemia with FLT3 mutations: a patent review
{{output}}
Introduction: Approximately one-third of all AML patients have a mutation in the Fms-like tyrosine kinase 3 (FLT3) gene, which is associated with a poor prognosis in these individuals. The 2017 approval of midostaurin, the first ... ...
